Brief: Tiziana Life Sciences To Pursue Development Of Intranasal Foralumab For The Treatment Of Long COVID
13/04/2023 12:15
April 13 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES TO PURSUE DEVELOPMENT OF INTRANASAL
FORALUMAB FOR THE TREATMENT OF LONG COVID
* TIZIANA LIFE SCIENCES LTD - ANNOUNCED IT PLANS TO
INVESTIGATE
INTRANASAL FORALUMAB FOR TREATMENT OF LONG COVID
* TIZIANA LIFE SCIENCES LTD - PLAN TO FILE AN IND IN 4Q 2023
Source text for Eikon: ID:nGNXbpXGfH
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study